Shorter studies (single dose or 1 month) have generally shown little to no effect [1][12]
Severe reactions (red flags): Widespread rash, significant swelling, blistering, facial swelling, or symptoms affecting multiple areas of the body
New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: 25% in a year might be a little fast
Mechanisms of Action Inhibition of Tyrosinase: Glutathione has been shown to inhibit the activity of tyrosinase, the enzyme responsible for the conversion of the amino acid tyrosine into melanin
-